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BACKGROUND Gastroesophageal reflux disease (GERD) and obesity are associated with esophageal
AND AIMS: adenocarcinoma (EAC). We hypothesized that the obesity–EAC relation is mediated by factors
secreted from adipocytes. Adiponectin is a peptide secreted by adipocytes, and its plasma levels are
inversely associated with obesity. We aimed to estimate the effect of circulating adiponectin on the
risk of Barrett’s esophagus (BE), an accepted precursor of EAC, controlling for GERD symptoms and
other potential confounders.
METHODS: We conducted a case–control study in cases of BE compared with controls without BE; most controls
had GERD. Odds ratios (OR), corresponding to associations with BE, were estimated from conditional
and unconditional logistic regression analyses of 50 matched pairs.
RESULTS: BE was inversely associated with plasma adiponectin level (OR for each 10-µg/mL decrement 4.7,
95% confidence interval [CI] 1.4–15.0) and positively associated with GERD duration ≥10 yr, male
gender, tobacco smoking, body mass index (BMI), waist circumference, and waist-to-hip ratio.
Further adjustment for GERD duration, tobacco use, and BMI increased the adiponectin–BE
association (OR 6.4, 95% CI 1.1–37.0), but the estimated OR was reduced when adjusting for
measures of abdominal obesity (e.g., OR 2.5, 95% CI 0.49–13.00) and further adjusting for gender
(OR 1.8, 95% CI 0.66–4.70).
CONCLUSIONS: Despite methodologic limitations, including the small sample size, our findings suggest that
adiponectin may be involved in the etiology of BE. Rather than simply a mechanical effect of obesity
promoting GERD, the effects of abdominal obesity on the risk of BE might be mediated by
adiponectin and other circulating factors.
(Am J Gastroenterol 2008;103:1358–1364)
INTRODUCTION
The incidence of esophageal adenocarcinoma (EAC) in the
United States is rising faster than that of any other cancer (1).
Barrett’s esophagus (BE) is associated with most, if not all,
EACs (2–4). Risk factors for EAC include gastroesophageal
reflux disease (GERD) and obesity (2, 3, 5). Obesity has
also been associated with GERD (5). Therefore, the effect of
obesity on EAC has been proposed to be mediated by a me-
chanical effect promoting GERD, and thereby promoting BE
(6, 7). As obesity is associated with EAC, even after adjusting
for GERD (5, 8), we hypothesized that the effect of obesity on
EAC and BE may not be solely due to the promotion of GERD.
Prior studies have shown an association between abdominal
obesity and BE, but no association, or a weaker association,
between total body obesity and BE (9–11). Abdominal adi-
pose tissue is biologically active; circulating factors secreted
from adipose tissue may mediate part of the effect of obesity
on the development of BE, EAC, or both. Candidate circu-
lating factors include interleukin-6, tumor necrosis factor-α,
leptin, ghrelin, adiponectin, insulin-like growth factor-1 or its
binding proteins, and others (12–17). Adiponectin is a peptide
secreted primarily from visceral adipocytes, for which serum
levels are inversely associated with obesity (18). Levels are
lower in men than in women, controlling for obesity (19).
Adiponectin inhibits inflammation and promotes apoptosis,
and deficiency of adiponectin has been associated with a num-
ber of epithelial cancers (18). We chose a priori to evaluate
the role of adiponectin because of these features and due to its
stable intrasubject levels across time and in relation to meals
(20–24). We hypothesized that adiponectin deficiency is a risk
factor for BE and performed a case–control study to examine
the association between circulating levels of adiponectin and
BE among patients undergoing elective upper endoscopy.
1358
Adiponectin and Barrett’s Esophagus 1359
METHODS
Subjects
The study was performed at the University of Michigan Medi-
cal Center and the Ann Arbor Veterans Affairs Medical Cen-
ter. Both centers provide a mix of primary, secondary, and
tertiary care. Both cases and controls were recruited when
they presented with clinical indications for elective upper en-
doscopy. Cases were patients with BE of at least 1 cm in
length (for the most part, these were prevalent cases), con-
firmed by histological identification of specialized intestinal
metaplasia within the tubular esophagus. Controls were pa-
tients without BE, who were individually matched to cases
on age (15-yr interval) and veteran/civilian status. If subjects
carried a diagnosis of BE from a previous endoscopy, but BE
was not confirmed by the endoscopy and biopsies at the time
of the study (N = 8, all short-segment on prior endoscopy
reports), they were not matched and were excluded from the
analysis. Patients were excluded from enrollment if they had
prevalent cancer, ascites, esophageal varices, coagulopathy,
or a history of esophagectomy, were pregnant, were a hos-
pital inpatient, were younger than 18 or greater than 79 yr
of age, or if the indication for endoscopy was weight loss of
≥10% or for placement of a feeding tube. The sample size
for the analyses presented is 50 matched case–control pairs.
The study was approved by the institutional review boards
of both centers, and all subjects provided written, informed
consent prior to enrollment.
Questionnaire and Anthropometry
Subjects were asked to complete self-administered question-
naires just prior to the endoscopy. A set of questions regarding
the presence, duration, quality, frequency of, and medica-
tions for GERD symptoms, including heartburn and reflux,
was based on variables previously found to be associated with
EAC (25). The questionnaires also queried history of tobacco
use. An important potential confounder of adiponectin defi-
ciency would be abdominal obesity, which is associated with
both adiponectin deficiency and BE. Weight, height, abdom-
inal circumference, and hip circumference were measured by
a trained assistant prior to the endoscopy, while the subject
wore only a hospital gown and undergarments.
Blood Samples
Fasting blood samples were drawn prior to the upper en-
doscopy. Plasma was separated and stored at −80◦C until
analyzed in duplicate for adiponectin using a commercially
available colorimetric sandwich enzyme-linked immunosor-
bent assay (B-Bridge, Sunnyvale, CA). We examined the
specificity of the relation between BE and adiponectin by ex-
amining a similar relation between BE and C-reactive protein
(CRP), serum levels of which are also associated with obe-
sity and have been associated with colorectal cancer (26, 27).
CRP was measured quantitatively in the clinical laboratory
of the Ann Arbor VA using the highly sensitive near-infrared
particle immunoassay methodology.
Endoscopy and Histology
Upper endoscopy was performed by clinical gastroenterol-
ogists at both study sites. The trained assistant was present
for all endoscopies and directed the endoscopists to abide
by standardized guidelines for diagnosing BE, hiatal her-
nia, and erosive esophagitis. These guidelines, with example
photographs, were posted in each endoscopy room at both
study sites. Digital photographs were obtained of the gastroe-
sophageal junction and the squamocolumnar junction in each
subject. The photographs were subsequently reviewed by the
principal investigator (JHR) to confirm the endoscopic ap-
pearance of BE. BE was suspected if salmon-colored mucosa
resided proximal to the gastric folds within the tubular esoph-
agus. The length of BE was documented, and four-quadrant
mucosal biopsies were obtained every 2 cm for histologic
confirmation. The presence and size of any hiatal hernia was
documented. One subject with Los Angeles Classification C
erosive esophagitis underwent repeat endoscopy after a heal-
ing course with a proton pump inhibitor, revealing normal
squamous lining. No other subjects without evidence of BE
on index endoscopy had erosive esophagitis that was more
severe than class B. Pathology specimens were prepared ac-
cording to the routine clinical protocol and interpreted by
clinical pathologists at each study site. The presence of spe-
cialized intestinal columnar mucosa was required for the di-
agnosis of BE.
Statistical Analysis
Data were entered into Microsoft Access (Microsoft Corpora-
tion, Redmond, WA), and then imported into SAS 9.1 statis-
tical software for analysis (SAS Institute, Cary, NC). Data
were assessed for range and logic inconsistencies. Cross-
tabs for categorical predictors and correlation coefficients
for continuous predictors were used to assess associations
between pairs of possible BE predictors among controls. Con-
ditional logistic regression analysis was used to estimate the
effect (odds ratio [OR] and 95% confidence interval [CI])
of adiponectin and other factors on BE, controlling for the
matching variables. Results are presented for several models,
involving adjustment for combinations of GERD duration,
smoking history, gender, body mass index (BMI), waist cir-
cumference, and waist-to-hip ratio (WHR). Because of the
small sample size (50 matched pairs) and the strong associ-
ation between gender (a known risk factor for BE) and vet-
eran/civilian status (a matching variable), we were not able to
adjust for gender plus other covariates in the matched analy-
sis. Thus, separate unconditional logistic regression analyses
were conducted, adjusting for the matching variable age but
not veteran/civilian status. Age was treated as a continuous
variable as similar results were found when using age as a
set of indicator variables. In addition, unconditional logistic
regression was performed in a set restricted to subjects with
GERD symptoms at least once per week while not taking
proton pump inhibitors or histamine type 2 receptor antago-
nists.
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RESULTS
As expected, cases and controls were similar in the matching
variables: the mean age was 60 yr in both groups, and 36% of
each group was of veterans. Most subjects were white, 92%
in cases and 96% in controls; 80% of cases and 54% of con-
trols were men. Among controls, the most common indica-
tions for the endoscopy were GERD refractory to medications
(33%), dysphagia (22%), screening for BE (18%), and iron-
deficiency anemia (10%). Among cases of BE, 84% were un-
dergoing endoscopy for surveillance of known BE (median
time since diagnosis was 5 yr, interquartile range 3–8 yr),
and the median length of the columnar segment was 3.0 cm
(range 1.0–18.0 cm). Four cases of BE were found to have
low-grade dysplasia, two were found to have high-grade dys-
plasia, and two were found to have invasive adenocarcinoma.
Among controls, the mean plasma level of adiponectin
was 11.4 µg/mL, ranging from 1.4 to 29.3 µg/mL. Waist cir-
cumference was highly correlated with WHR or BMI among
controls without BE (Pearson’s correlation coefficient [r] =
0.71, P < 0.0001 for waist circumference and WHR; r =
0.80, P < 0.0001 for waist circumference and BMI). How-
ever, BMI and WHR were less correlated with each other (r
= 0.22, P = 0.12). Adiponectin levels were weakly to mod-
erately correlated with WHR (r = −0.37, P = 0.008), waist
circumference (r = −0.40, P = 0.005), BMI (r = −0.19, P
= 0.18), and age (r = 0.38, P = 0.007), and nearly uncor-
related with GERD duration (r = −0.01, P = 0.92). Male
controls trended toward lower levels of adiponectin than fe-
male controls (mean ± standard deviation 10.3 ± 6.6 µg/mL
vs 12.6 ± 5.6 µg/mL, P = 0.19). Veteran and civilian controls
had similar adiponectin levels (11.2 ± 6.6 µg/mL vs 11.5 ±
6.1 µg/mL, P = 0.89). Among cases of BE, the mean plasma
level of adiponectin was 8.4 µg/mL, ranging from 1.6 to 18.6
µg/mL. Adiponectin was weakly correlated with the number
of years since the initial diagnosis of BE (r = 0.24, P = 0.14).
Conditional logistic regression analysis showed that longer
GERD duration, male gender, BMI, waist circumference, and
WHR were all associated with BE (Table 1, models B–F). As
hypothesized, lower levels of circulating adiponectin were
also associated with BE: for each 10-µg/mL decrement in
adiponectin, there was an increased odds of BE (OR 4.7, 95%
CI 1.4–15.0). Level of CRP was not associated with BE (OR
0.99, 95% CI 0.64–1.50). The estimated effect of adiponectin
was not reduced when adjusting for GERD duration, smok-
ing status, and BMI (Table 1, model J). When adjusting for
abdominal obesity, however, the estimated effect of adiponec-
tion was reduced; for example, adjusting for WHR plus the
other covariates, the OR for adiponectin deficiency was 2.5
(95% CI 0.49–13.00) (Table 1, models K and L).
In order to adjust for gender, we broke the matched pairs
and used unconditional logistic regression to estimate effects,
adjusting for age but not veteran/civilian status. After adjust-
ing for gender, the estimated effect of adiponectin on BE
was reduced, but not eliminated, in these analyses (Table 2).
For example, adjusting for age, GERD duration, gender, and
Table 1. Odds Ratios for the Association Between Predictors and
Barrett’s Esophagus: Results of Conditional Logistic Regression
Analyses




B GERD duration ≥10 yr vs <10 yr 2.9 (1.2–6.8)
C Ever smoker vs never smoker 6.3 (1.9–21.0)
D BMI (5-kg/m2 increment)∗ 1.5 (1.0–2.4)
E Waist circumference (10-cm
increment)∗
1.6 (1.1–2.2)
F Waist/hip ratio (0.1 increment)∗ 2.6 (1.5–4.7)








GERD duration ≥10 yr vs <10 yr 3.0 (0.89–10.00)




GERD duration ≥10 yr vs <10 yr 3.0 (0.84–10.00)
Ever smoker vs never smoker 7.5 (1.7–33.0)
BMI (5-kg/m2 increment)∗ 0.87 (0.42–1.80)
K Adiponectin (10-µg/mL decrement)∗ 4.9 (0.79–30.00)
GERD duration ≥10 yr vs <10 yr 2.8 (0.75–11.00)







GERD duration ≥10 yr vs <10 yr 2.3 (0.57–9.00)
Ever smoker vs never smoker 6.0 (1.3–27.0)
Waist/hip ratio (0.1 increment)∗ 1.7 (0.84–3.50)
Each model only included the covariates for which results are displayed (1–4 covariates
in each model); for instance, model L included adiponectin, GERD duration, smoking
status, and waist/hip ratio.
∗The odds ratio for a continuous predictor is estimated for a specified difference in
that exposure (indicated in parentheses after the predictor).
OR (95% CI) = odds ratio (95% confidence interval); BMI = body mass index; CRP
= C-reactive protein.
WHR, the estimated OR for adiponectin deficiency was 1.8
(95% CI 0.66–4.70). The estimated effect of male gender was
reduced after adjusting for adiponectin, and reduced more so
after adjusting for WHR. Restricting the analyses to subjects
with GERD symptoms at least once per week while off pro-
ton pump inhibitors or histamine type 2 receptor antagonists
(45 cases of BE and 34 controls) resulted in similar estimates
of the adiponectin effect (Table 3). For example, adjusting
for age, gender, and WHR, the estimated OR for adiponectin
deficiency was 1.7 (95% CI 0.60–4.90). Current or past to-
bacco smoking remained strongly associated with BE in all
analyses.
DISCUSSION
In our case–control study of 50 BE cases and matched con-
trols undergoing elective endoscopy for other clinical indica-
tions, we found an inverse association between the circulating
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Table 2. Odds Ratios for the Association Between Predictors and
Barrett’s Esophagus: Results of Unconditional Logistic Regression
Analyses Adjusted for Age
Model Covariate OR (95% CI)
A Male vs female 4.5 (1.8–12.0)
B Adiponectin (10-µg/mL decrement)∗ 2.3 (0.97–5.60)
Male vs female 3.2 (1.2–8.8)
C Male vs female 1.4 (0.40–4.90)
Waist/hip ratio (0.1 increment)∗ 2.3 (1.2–4.2)
D Adiponectin (10-µg/mL decrement)∗ 2.4 (0.95–6.10)
GERD duration ≥10 yr vs <10 yr 3.9 (1.5–10.0)
Male vs female 3.3 (1.2–9.2)
E Adiponectin (10-µg/mL decrement)∗ 1.9 (0.76–4.90)
GERD duration ≥10 yr vs <10 yr 4.0 (1.5–11.0)
Male vs female 3.8 (1.2–11.0)
BMI (5-kg/m2 increment)∗ 1.6 (0.99–2.50)
F Adiponectin (10-µg/mL decrement)∗ 1.8 (0.69–4.70)
GERD duration ≥10 yr vs <10 yr 3.9 (1.4–11.0)
Male vs female 2.7 (0.90–7.90)
Waist circumference (10-cm increment)∗ 1.4 (0.99–1.90)
G Adiponectin (10-µg/mL decrement)∗ 1.8 (0.66–4.70)
GERD duration ≥10 yr vs <10 yr 3.5 (1.3–9.5)
Male vs female 1.4 (0.39–5.40)
Waist/hip ratio (0.1 increment)∗ 1.9 (0.99–3.60)
Each model only included the covariates for which results are displayed (1–4 covariates
in each model), plus age as a continuous variable.
∗The odds ratio for a continuous predictor is estimated for a specified difference in that
exposure (indicated in parentheses after the predictor).
OR (95% CI) = odds ratio (95% confidence interval); BMI = body mass index; CRP
= C-reactive protein.
level of adiponectin and the presence of BE. The magnitude
of this association was not reduced when adjusting for GERD,
tobacco use, and BMI; however, adjustment for gender and
abdominal obesity did reduce the association. Although these
latter adjustments did not eliminate the association between
adiponectin and BE, the small sample size resulted in impre-
cise OR estimates (wide CIs), making chance an alternative
explanation for these findings.
Research on the pathogenesis of BE and EAC has largely
focused on GERD as an etiologic agent. However, approxi-
mately 40% of EAC patients report never having had GERD
symptoms (2, 28). Furthermore, animal models of severe ero-
sive esophagitis are inefficient at producing the complications
of BE or EAC, suggesting that other factors may be neces-
sary (29). Genetic predisposition may be one such factor,
but the human species cannot be evolving rapidly enough to
account for the increasing incidence of EAC over the last
few decades (1). An environmental or behavioral cause is
much more likely. We found that among patients referred for
endoscopy, most with GERD, those diagnosed with BE are
more likely to have smoked than those patients without BE,
raising the possibility that smoking is a risk factor for BE.
Nonetheless, tobacco use is on the wane in the United States.
In contrast, Jeon et al. have shown that the period effect on
the gender- and age-specific prevalence of obesity matches
the period effect on the gender- and age-specific incidence
of EAC over the last decades, suggesting a possible causal
link (30). While obesity may promote GERD by mechanical
or physiologic mechanisms, the association of obesity with
Table 3. Odds Ratios for the Association Between Predictors and
Barrett’s Esophagus Among GERD Patients: Results of Uncondi-
tional Logistic Regression Analyses Adjusted for Age, Restricted
to Subjects With GERD at Least Once per Week (45 Cases and 34
Controls)
Model Covariate OR (95% CI)
A Adiponectin (10-µg/mL decrement)∗ 3.1 (1.2–7.9)
B GERD duration ≥10 yr vs <10 yr 2.6 (0.88–7.60)
C Ever smoker vs never smoker 6.4 (2.2–19.00)
D BMI (5-kg/m2 increment)∗ 1.5 (0.96–2.40)
E Waist circumference (10-cm increment)∗ 1.5 (1.1–2.1)
F Waist/hip ratio (0.1 increment)∗ 2.3 (1.3–3.8)
G Male vs female 4.2 (1.5–12.00)
H CRP (1-mg/L increment)∗ 0.97 (0.60–1.60)
I Adiponectin (10-µg/mL decrement)∗ 2.2 (0.81–6.00)
Male vs female 2.9 (0.93–9.10)
J Adiponectin (10-µg/mL decrement)∗ 1.8 (0.62–5.00)
Male vs female 3.4 (1.0–11.0)
BMI (5-kg/m2 increment)∗ 1.5 (0.95–2.50)
K Adiponectin (10-µg/mL decrement)∗ 1.6 (0.57–4.80)
Male vs female 2.4 (0.76–7.90)
Waist circumference (10-cm increment)∗ 1.4 (0.95–1.90)
L Adiponectin (10-µg/mL decrement)∗ 1.7 (0.60–4.90)
Male vs female 1.3 (0.31–5.60)
Waist/hip ratio (0.1 increment)∗ 1.8 (0.90–3.70)
Each model only included the covariates for which results are displayed (1–4 covariates
in each model), plus age as a continuous variable.
∗The odds ratio for a continuous predictor is estimated for a specified difference in that
exposure (indicated in parentheses after the predictor).
OR (95% CI) = odds ratio (95% confidence interval); BMI = body mass index; CRP
= C-reactive protein.
EAC remains present even when adjusting for GERD symp-
toms, suggesting a different pathway (5, 8). In this study of
patients referred for endoscopy for clinical indications, we
found that deficiency of plasma levels of adiponectin, a pep-
tide secreted primarily from visceral adipocytes, is associated
with BE, even after adjusting for duration of GERD symp-
toms. Male gender is also widely recognized to be a risk factor
for both BE and EAC, but to our knowledge, there has yet to
be any documented mechanism for these effects (8). It is pos-
sible that the positive association between male gender and
BE might be explained, in part, by a low adiponectin level,
which is positively associated with both male gender and BE.
The magnitude of the estimate of the effect of male gender
was reduced after adjusting for either adiponectin or WHR.
Adiponectin is the most abundant gene product of
adipocytes, and if it is produced by other human tissues at
all, it appears to be produced by them at low levels (19,
31). Adiponectin levels are inversely associated with the
presence of colorectal adenomas and with cancers of the
colon, stomach, uterus, breast, and prostate (18, 32). In a
prospective cohort study, low adiponectin was found to be
associated with the subsequent development of colorectal
cancer (33). Multiple potential signaling pathways for this
association have been described (18, 34–36). Adiponectin
shares homology with tumor necrosis factor-α, acts on dis-
tant tissues to promote apoptosis, suppresses proliferation,
and suppresses angiogenesis (18, 37, 38). Therefore, defi-
ciency of adiponectin may be involved in the promotion and
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progression of carcinogenesis. One potential mechanism of
action is adiponectin’s suppression of the extracellular signal-
regulated kinases 1 and 2 (ERK 1/2) (35). Subjects with BE
have abnormal activation of ERK 1/2 in squamous epithe-
lium, promoting proliferation and inhibiting apoptosis; it has
been proposed that failure to downregulate ERK 1/2 might
promote a metaplastic response to reflux (36). That failure to
downregulate ERK 1/2, and the resultant uncontrolled pro-
liferation, might be due to deficiency of adiponectin. In addi-
tion, deficiency of adiponectin might promote uncontrolled
esophageal inflammation in the setting of GERD. The lack of
an association between BE and levels of CRP (a circulating
factor whose levels are also associated with obesity) suggests
that the association between BE and deficiency of adiponectin
is a specific one and may be causal. Studies of the effects of
adiponectin in animal models of esophagitis and in cell line
cultures are necessary to determine whether adiponectin de-
ficiency has a causative role in the development of BE and
EAC.
Our findings may have been influenced by the use of two
imperfect (proxy) measures of visceral fat volume, waist cir-
cumference and WHR. Adjusting for those two measures
may not have completely controlled for abdominal obesity,
and adiponectin’s attenuation of the estimated effect of waist
circumference or WHR for BE could be due to a closer ap-
proximation of visceral fat volume by adiponectin levels than
by either of those measures. Given the small sample size and
the matched design, we may not have completely adjusted for
confounders, and this study cannot provide a precise estimate
of the hypothesized adiponectin effect on BE. Nonetheless,
the fact that low adiponectin remains associated with BE
even when adjusting for GERD suggests a mechanism for
the association of visceral fat and BE, aside from the one
promoting GERD. Adipocytes secrete many factors into the
circulation, many of which have effects on inflammation and
some of which might also influence metaplasia or progres-
sion of neoplasia. Adiponectin is unlikely to be the only such
factor to be associated with BE. Levels of adiponectin are
likely to be closely associated with levels of these other un-
measured secreted factors. Our results suggest that the effect
of adiponectin may have been confounded by covariates such
as obesity and male gender, and we cannot rule out that the
adjusted association was a chance finding. Thus, our results
suggest that adiponectin and/or abdominal obesity affect the
risk of BE, but we cannot precisely separate their effects in
this study due to the small sample size. Another limitation is
that the control group included patients with multiple indica-
tions for endoscopy rather than a specific population at risk
for BE, and that might have introduced selection bias in the
estimation of effects, but the direction and magnitude of such
bias is difficult to predict. However, an analysis restricted to
subjects with GERD at least once per week (the group of
patients who are recommended to undergo screening for BE)
showed similar results. Furthermore, this study cannot deter-
mine whether adiponectin deficiency is associated with BE
among subjects without GERD. Finally, the study is limited
by temporal ambiguity as the measurement of adiponectin
did not precede the development of BE.
In summary, we observed that among patients referred for
endoscopies, most with GERD, those diagnosed with BE have
lower adiponectin levels, on average, than do those without
BE. This association may mean that a lower adiponectin level
increases the risk of BE, but additional research is needed to
make a causal inference. Thus, our findings might partly ex-
plain the effects of abdominal obesity and male gender on BE.
The relentless obesity epidemic may portend a progressively
rising incidence of EAC over the coming decades. Prevention
of mortality from EAC will require a fuller understanding of
the risk factors and pathogenesis for this cancer type. Identi-
fication of relations with additional secreted factors might be
exploited to develop panels of biomarkers for the identifica-
tion of patients at risk for BE and EAC or for the development
of novel chemopreventive strategies for EAC.
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STUDY HIGHLIGHTS
What Is Current Knowledge
 Obesity is associated with Barrett’s esophagus (BE)
and esophageal adenocarcinoma.
 This relationship is generally believed to be mediated
by gastroesophageal reflux disease (GERD).
 Adiponectin is secreted by adipocytes, and its plasma
levels are inversely related to obesity.
 Adiponectin may suppress tumorgenesis, and its circu-
lating levels are inversely related to the risk of a number
of epithelial cancers.
What Is New Here
 Circulating levels of adiponectin are inversely associ-
ated with BE among patients referred for endoscopy.
 The association between adiponectin level and BE does
not appear to be due entirely to confounding by GERD
or other measured risk factors for BE.
 Rather than simply a mechanical effect of obesity pro-
moting GERD, the effect of obesity on the risk of BE
might be mediated by adiponectin and other circulating
factors.
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